A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Neoplasm Recurrence, Local
  • Phosphatidylinositol 3-Kinase

abstract

  • The addition of PX-866 to docetaxel did not improve PFS, response rate, or OS in patients with advanced, refractory NSCLC without molecular preselection.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/JTO.0000000000000183

PubMed ID

  • 24926548

Additional Document Info

start page

  • 1031

end page

  • 5

volume

  • 9

number

  • 7